Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ:HZNP)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Named to the 2023 Fortune 100 Best Companies to Work For List
From Horizon Therapeutics plc
Via Business Wire
News headline image
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
News headline image
New Analysis of MRI Findings Show UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Asymptomatic Optic Nerve Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
News headline image
Real-World Experience Shows TEPEZZA® (teprotumumab-trbw) Was Effective in Treating People With Dysthyroid Optic Neuropathy (DON)
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc - Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Opens Applications for #RAREis Global Advocate Grant Program
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Announces Voting Results from Special Shareholder Meetings
From Horizon Therapeutics plc
Via Business Wire
News headline image
New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
From Horizon Therapeutics plc
Via Business Wire
News headline image
Rule 15 (c) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
News headline image
HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Rule 17 (b) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
News headline image
Rule 17 (a) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
From Horizon Therapeutics plc
Via Business Wire
News headline image
Rule 2.12 Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
News headline image
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
News headline image
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
From Horizon Therapeutics plc
Via Business Wire
News headline image
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
News headline image
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
News headline image
HORIZON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Form 8.1 Opening Position Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
News headline image
HZNP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Horizon Therapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
From Horizon Therapeutics plc
Via Business Wire
News headline image
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
From Horizon Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.